Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
GLP-1 weight-loss drugs show unexpected psychiatric benefits in largest study to date

GLP-1 weight-loss drugs show unexpected psychiatric benefits in largest study to date

New Capabilities

A Swedish study of nearly 100,000 people finds semaglutide users experienced 42% fewer psychiatric hospitalizations, raising the prospect of a new class of mental health treatment

March 22nd, 2026: Largest study finds semaglutide cuts psychiatric crises by 42%

Overview

Drugs originally designed to control blood sugar and reduce weight may also protect the brain. A study of 95,490 people in Sweden, published in The Lancet Psychiatry on March 22, 2026, found that users of semaglutide—the compound in the blockbuster drugs Ozempic and Wegovy—experienced 42% fewer psychiatric hospitalizations, 44% less worsening depression, and 47% fewer substance-use-related crises compared to periods when they were not taking the drug.

The finding arrives at a pivotal moment. In January 2026, the United States Food and Drug Administration (FDA) removed suicide-risk warnings from GLP-1 drug labels after concluding the medications posed no psychiatric danger. Now researchers are asking a bolder question: could these drugs, already prescribed to tens of millions worldwide for diabetes and obesity, represent an entirely new avenue for treating mental illness? The answer hinges on whether randomized clinical trials—designed to prove causation, not just correlation—can confirm what the observational data suggests.

Why it matters

If confirmed, drugs already taken by tens of millions could become a new treatment class for depression, anxiety, and addiction.

Play on this story Voices Debate Predict

Key Indicators

42%
Reduction in psychiatric decompensation
Composite measure including psychiatric hospitalization, extended sick leave, self-harm hospitalization, and death by suicide during semaglutide use versus non-use periods
95,490
Study participants
People with pre-existing depression or anxiety who used antidiabetic medications in Sweden between 2009 and 2022
47%
Reduction in substance use disorder crises
Lower rate of hospitalizations and extended sick leave related to substance use disorders during GLP-1 treatment
$62B+
Global GLP-1 market size
Estimated annual revenue for GLP-1 receptor agonist drugs in 2025, projected to exceed $130 billion by 2035

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Heidi Taipale
Heidi Taipale
Active researcher
 Jari Tiihonen
Jari Tiihonen
Active researcher

Organizations Involved

Novo Nordisk
Novo Nordisk
Pharmaceutical company
Manufacturer of semaglutide (Ozempic, Wegovy)

Danish pharmaceutical company that manufactures semaglutide, the GLP-1 drug showing the strongest psychiatric benefit signal in the new study.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Removed psychiatric risk warnings from GLP-1 labels in January 2026

The FDA reversed course on GLP-1 psychiatric warnings in January 2026, requesting removal of suicidal behavior labels based on a meta-analysis of 91 trials and a study of over 2.2 million users.
Karolinska Institutet
Karolinska Institutet
Research university
Co-produced the March 2026 study

One of Europe's leading medical universities, based in Stockholm, and a co-institutional home for the research group behind the Lancet Psychiatry study.

Timeline

  1. Largest study finds semaglutide cuts psychiatric crises by 42%

    Research

    A study of 95,490 people published in The Lancet Psychiatry found semaglutide reduced psychiatric decompensation by 42%, with 44% less worsening depression, 38% less worsening anxiety, and 47% fewer substance-use-disorder crises. The within-individual design compared each person's outcomes during treatment versus non-treatment periods.

  2. FDA removes suicide-risk warnings from GLP-1 drug labels

    Regulatory

    Based on a meta-analysis of 91 trials and a retrospective study of 2.2 million users, the FDA requested drug manufacturers remove suicidal behavior and ideation warnings from GLP-1 receptor agonist labels—a significant reversal from the caution that followed rimonabant's withdrawal.

  3. Meta-analysis of 80 trials finds no psychiatric harm from GLP-1 drugs

    Research

    A JAMA Psychiatry meta-analysis of 80 double-blind, placebo-controlled trials with 107,860 adults concluded GLP-1 receptor agonists did not increase psychiatric side effects compared to placebo, with small improvements in well-being. A critical limitation: people with psychiatric histories were generally excluded.

  4. Semaglutide reduces heavy drinking in randomized trial

    Research

    A randomized controlled trial published in JAMA Psychiatry found low-dose semaglutide significantly reduced weekly alcohol cravings and heavy drinking days in 48 patients with alcohol use disorder over nine weeks.

  5. Major veterans study links GLP-1 drugs to reduced addiction risk

    Research

    Washington University researchers analyzing over 600,000 veterans found GLP-1 medications associated with 18–25% reduced risk of developing substance use disorders across all major addictive substances, with 50% fewer drug-related deaths at three years among those with pre-existing disorders.

  6. Pharmacovigilance studies yield conflicting psychiatric signals

    Research

    Multiple studies using the FDA's adverse event reporting system produced contradictory results—some found elevated psychiatric event reports with semaglutide, while others found no pattern.

  7. First systematic reviews examine GLP-1 antidepressant effects

    Research

    A systematic review and meta-analysis in The American Journal of Geriatric Psychiatry examined early evidence for antidepressant effects of GLP-1 receptor agonists, finding preliminary signals.

  8. FDA approves Wegovy for weight management

    Regulatory

    Semaglutide received FDA approval at higher doses for chronic weight management, triggering an explosion in off-label and on-label prescriptions worldwide.

  9. FDA approves Ozempic for type 2 diabetes

    Regulatory

    Novo Nordisk's semaglutide received FDA approval for diabetes under the brand name Ozempic, beginning its path to becoming one of the best-selling drugs in history.

  10. Rimonabant withdrawn over psychiatric side effects

    Regulatory

    The European Medicines Agency suspended the anti-obesity drug rimonabant after reports of severe depression and suicidality. The withdrawal created lasting caution about obesity drugs and mental health, leading regulators to require psychiatric warnings on subsequent weight-loss medications.

Scenarios

Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.

Log in to predict. Track your picks, climb the leaderboard. Log in Sign Up
1

Randomized trials confirm psychiatric benefits, FDA approves new indication

If purpose-built randomized controlled trials in psychiatric populations replicate the observational findings, semaglutide or similar GLP-1 drugs could receive FDA approval for psychiatric indications—depression, anxiety, or substance use disorders. This would represent the most significant new class of psychiatric medication since ketamine-based treatments. Novo Nordisk and Eli Lilly would likely race to run the trials, given the enormous market expansion. The trigger would be positive Phase 2 results in the next two to three years.

Discussed by: Psychiatric Times, Brown University addiction researchers, and multiple experts in Science Media Centre commentary
Consensus —
2

Benefits prove indirect—weight loss and metabolic improvement explain the effect

Skeptics note that the psychiatric improvements could stem entirely from downstream effects of weight loss, better blood sugar control, improved sleep, and enhanced quality of life—rather than any direct action on the brain. If randomized trials show that GLP-1 drugs produce no psychiatric benefit beyond what comparable weight loss achieves, the drugs would not earn a psychiatric indication, though the metabolic-mental health connection itself would be an important finding for treatment approaches.

Discussed by: Thomas Rutledge (VA San Diego Healthcare System) and multiple Science Media Centre experts
Consensus —
3

Off-label psychiatric prescribing surges before trials are complete

Given the massive prescribing base and mounting evidence, psychiatrists and primary care physicians may begin prescribing GLP-1 drugs off-label for patients with treatment-resistant depression, anxiety, or substance use disorders—particularly patients who also have metabolic comorbidities. This pattern has precedent: ketamine was widely used off-label for depression years before esketamine received formal FDA approval. Insurance coverage battles and cost barriers would limit uptake, but the trend could accelerate.

Discussed by: APA Monitor, Medscape, and psychiatrists commenting on the growing body of observational evidence
Consensus —
4

Long-term data reveal psychiatric side effects in a subset of patients

Some adverse event database analyses have found elevated reports of depression and anxiety with GLP-1 drugs, and patient reports of emotional blunting or flattened affect have circulated on social media. If larger, longer-term studies identify a subset of patients who experience psychiatric deterioration—even as others improve—regulators might require risk stratification screening before prescribing, complicating the narrative of broad psychiatric benefit.

Discussed by: Pharmacovigilance researchers, FDA adverse event analysts, and patient advocacy groups reporting emotional blunting
Consensus —

Historical Context

Sildenafil repurposing: from failed heart drug to Viagra (1991–1998)

1991–1998

What Happened

Pfizer developed sildenafil as a treatment for angina and hypertension. Clinical trials in Wales showed disappointing cardiovascular results, but male participants reported an unexpected side effect: sustained erections. Pfizer pivoted the drug's development entirely, and the FDA approved Viagra for erectile dysfunction in March 1998.

Outcome

Short Term

Viagra generated $1 billion in sales in its first year, becoming one of the fastest-adopted drugs in history.

Long Term

Sildenafil was later approved a third time—as Revatio for pulmonary arterial hypertension—making it one of the most successfully repurposed compounds in pharmaceutical history.

Why It's Relevant Today

The Viagra story demonstrates how a drug's most important medical application can emerge from unexpected clinical observations. GLP-1 drugs, developed for metabolic conditions, may be following a similar trajectory if psychiatric benefits are confirmed.

Lithium's psychiatric discovery (1949–1970)

1949–1970

What Happened

Australian psychiatrist John Cade discovered lithium's calming properties accidentally in 1949 while injecting lithium-urine solutions into guinea pigs as part of unrelated research. He published clinical results showing lithium improved mania, but adoption was slow—partly because lithium is a natural element that no company could patent. Danish psychiatrist Mogens Schou championed lithium through rigorous trials over two decades.

Outcome

Short Term

The FDA did not approve lithium for bipolar disorder until 1970, more than twenty years after Cade's discovery.

Long Term

Lithium remains the only medication proven to prevent suicide in mood disorders and is still considered the gold standard for bipolar maintenance therapy, despite being one of the oldest and cheapest psychiatric drugs available.

Why It's Relevant Today

Lithium illustrates both the promise and the friction of psychiatric drug discovery through serendipity. GLP-1 drugs face a faster path—they are already widely prescribed, well-characterized, and backed by large pharmaceutical companies—but the same fundamental question applies: can observational signals survive the rigor of controlled trials?

Rimonabant withdrawal: the anti-obesity drug that worsened mental health (2006–2008)

June 2006–October 2008

What Happened

Sanofi-Aventis launched rimonabant, an endocannabinoid receptor blocker, as an anti-obesity treatment in Europe in 2006. Post-marketing surveillance revealed a pattern of severe depression, anxiety, and suicidality. The European Medicines Agency suspended rimonabant in October 2008, and the FDA never approved it in the United States.

Outcome

Short Term

Rimonabant was pulled from all markets. Sanofi-Aventis wrote off its investment in the drug.

Long Term

The episode created lasting regulatory caution about the psychiatric effects of weight-loss drugs. Subsequent obesity medications, including GLP-1 drugs, were required to carry psychiatric warnings—the same warnings the FDA removed from GLP-1 labels in January 2026.

Why It's Relevant Today

Rimonabant's failure is the direct reason GLP-1 drugs carried psychiatric warnings in the first place. The new study represents a complete inversion of the rimonabant story: rather than weight-loss drugs causing psychiatric harm, they may provide psychiatric protection. This reversal makes the evidence bar for a psychiatric indication both higher and more consequential.

Sources

(8)
+2
The Lancet Psychiatry ScienceDaily Global News Karolinska Institutet Medscape U.S. Food and Drug Administration JAMA Psychiatry Science Media Centre